Chief Executive Officer & Executive Director, AstraZeneca PLC
Most recently reported pay: $8.3M. No year-by-year proxy breakdown is on file — common for foreign private issuers and recently listed companies, which do not file a US proxy statement.
Names, titles and pay as reported by the company and its SEC filings, via Financial Modeling Prep. Reference only — nothing here is investment advice, and no affiliation with or endorsement by the people listed is implied.
New Strong Sell Stocks for September 15th
Sep 15, 2026https://www.zacks.com/stock/news/2989561/new-strong-sell-stocks-for-september-15th?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|new_zacks_5_rank_stocks-2989561sentiment -1.00
Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company
Sep 14, 2026https://www.globenewswire.com/news-release/2026/09/14/3360712/0/en/cellectis-announces-strategic-transformation-to-in-vivo-gene-editing-company.htmlsentiment +0.00
Should You Buy Bristol Myers Squibb Stock Right Now for the Yield Alone?
Sep 13, 2026https://www.fool.com/investing/2026/09/13/should-you-buy-bristol-myers-squibb-stock-yield/sentiment +0.00
AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears
Sep 13, 2026https://www.marketbeat.com/instant-alerts/event-astrazeneca-copd-drug-cuts-exacerbations-as-fda-priority-review-nears-2026-09-13/sentiment +0.80
Panmure and Cavendish reiterate buy on Hutchmed after GSK deal
Sep 3, 2026https://www.proactiveinvestors.co.uk/companies/news/1098046sentiment +0.60
AstraZeneca lung cancer therapy combination shows promise in advanced study
Sep 1, 2026https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-lung-cancer-therapy-combination-shows-promise-advanced-study-2026-09-01/sentiment +0.80
